BriaCell Therapeutics(BCTX)
$3.59-0.10 (-2.71%)
BCTX
BriaCell Therapeutics financials statements
$3.59
At close:-0.10 (-2.71%)
BriaCell Therapeutics (BCTX) Ratios
336 Followers
BriaCell Therapeutics Ratios
BCTX's free cash flow for Q4 2026 was C$-5.88M. For the 2026 fiscal year, BCTX's free cash flow was decreased by C$-330.00 and operating cash flow was C$-5.88M. See a summary of the company’s cash flow.
| Ratios | Jul 26 | Jul 25 | Jul 24 | Jul 23 | Jul 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.76 | 5.01 | 0.49 | 14.96 | 45.00 |
| Quick Ratio | 2.76 | 5.01 | 0.49 | 14.96 | 45.00 |
| Cash Ratio | 1.23 | 2.64 | 0.12 | 11.80 | 43.61 |
| Solvency Ratio | -4.40 | -6.13 | -0.00 | -0.66 | -0.36 |
| Operating Cash Flow Ratio | -3.64 | -7.14 | -3.23 | -13.18 | -13.27 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 14.02M | C$ 15.66M | C$ -4.90M | C$ -3.99M | C$ 10.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.44 | 1.21 | -2.46 | -7.19 | 4.12 |
| Debt Service Coverage Ratio | 0.00 | -732.82 | 0.00 | 0.00 | -34808.71 |
| Interest Coverage Ratio | 0.00 | -735.71 | 0.00 | 0.00 | -15616.96 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.09 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.27 | 0.38 | 18.78 | 0.78 | 1.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 98.81% | 99.08% | 97.15% | 100.00% | 43.15% |
| EBT Per EBIT | 97.98% | 97.62% | 14.80% | 87.24% | 175.54% |
| Return on Assets (ROA) | -150.27% | -122.60% | -0.11% | -74.74% | -27.20% |
| Return on Equity (ROE) | -216.04% | -148.44% | 0.28% | 537.49% | -112.12% |
| Return on Capital Employed (ROCE) | -234.64% | -155.30% | 2.90% | -91.76% | -36.72% |
| Return on Invested Capital (ROIC) | -234.64% | -155.30% | 2.90% | -91.07% | -36.72% |
| Return on Tangible Assets | -151.35% | -123.65% | -0.12% | -75.34% | -27.35% |
| Earnings Yield | -146.64% | -623.23% | -0.00% | -1.48% | -0.89% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.02 | 0.03 | 0.02 | 0.02 | 0.04 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -21074.71 | -11142.95 | -22951.83 | -20017.80 | -8723.10 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 21074.71 | 11142.95 | 22951.83 | 20017.80 | 8723.10 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -5.80 | -67.39 | -21.99 | -22.80 | -12.09 |
| Free Cash Flow Per Share | -5.83 | -67.39 | -22.41 | -22.80 | -12.09 |
| Dividend Paid and CapEx Coverage Ratio | -225.51 | 0.00 | -52.82 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -225.51 | 0.00 | -52.82 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -120.90% | -667.26% | -14.50% | -1.74% | -0.96% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.68 | -0.16 | -25621.43 | -67.40 | -112.12 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.47 | 0.24 | -71.14 | -362.25 | 125.71 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.83 | -0.15 | -6.89 | -57.62 | -104.00 |
| Price-to-Operating Cash Flow Ratio | -0.83 | -0.15 | -7.02 | -57.62 | -104.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.00 | 326.92 | 2.93 | 2.49 |
| Enterprise Value Multiple | -0.39 | 0.23 | -3673.32 | -49.47 | -36.93 |
| Enterprise Value | 14.30M | -6.26M | 168.62M | 1.35B | 1.26B |
| EV to EBITDA | -0.39 | 0.23 | -3673.32 | -49.47 | -36.93 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.49 | 0.22 | -6.86 | -56.73 | -100.71 |
| EV to Operating Cash Flow | -0.49 | 0.22 | -6.99 | -56.73 | -100.71 |
| Tangible Book Value Per Share | 3.07 | 40.67 | -2.63 | -3.83 | 9.78 |
| Shareholders’ Equity Per Share | 3.27 | 42.40 | -2.17 | -3.63 | 10.00 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.01 | -0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -7.07 | -62.95 | -0.01 | -19.50 | -11.21 |
| Tax Burden | 0.99 | 0.99 | 0.97 | 1.00 | 0.43 |
| Interest Burden | 0.98 | 0.98 | 0.15 | 0.75 | 0.79 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.82 | 1.07 | 4.89 | 1.17 | 0.47 |
Currency in CAD
